Several recent randomized clinical trials have demonstrated that initial targeted therapy with combined BRAF and MEK inhibition is more effective in metastatic melanoma (MM) than single agent. A recent comprehensive meta-analysis confired that concurrent inhibition of BRAF and MEK was the most effective therapeutic modality compared with single BRAF or MEK inhibition for patients with MM.
- PubMed and trial registries searched for randomized clinical trials of targeted therapy
- Outcomes data extracted on progression-free survival (PFS), objective response rate (ORR), and overall survival (OS)
- Network meta-analysis (Bayesian statistical model) performed to evaluate relative hazard ratio (HR) for PFS and OS, odds ratio (OR) for ORR
- 16 el...